Tags

Type your tag names separated by a space and hit enter

Maternal and developmental toxicity study of sodium azide in rats.
Regul Toxicol Pharmacol. 2008 Nov; 52(2):158-62.RT

Abstract

Sodium azide (NaN(3)) is being proposed for use as an active ingredient to control a broad spectrum of soil borne pathogens including insects, weeds, nematodes, fungi, and bacteria. The purpose of this study was to determine the maternal and developmental toxicity of NaN(3) in rats. Sperm-positive Sprague-Dawley rats were treated with NaN(3) via oral gavage once daily from Gestation Day (GD) 6 through 19 at respective dose levels of 0, 1, 5, and 17.5mg/kg/day. From GD 10-12, the high-dose was reduced to 10mg/kg/day due to maternal mortality. Cesarean section was performed on GD 20 and implantation and resorptions sites, live and dead fetuses were counted. Fetuses were weighed, sexed externally and processed for gross external, visceral and skeletal examinations. A high rate of maternal mortality; reduced gestation body weight, gestation body weight changes and food consumption; decreased corrected body weight and corrected weight gain were observed at 17.5/10mg/kg/day. Fetal weight was also reduced at 17.5/10mg/kg/day. There were no maternal deaths, clinical signs or body weight effects that were considered related to NaN(3) at 1 and 5mg/kg/day. No increase in the incidence of malformations and variations were observed at any of the doses evaluated. Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) and the Lowest Observed Adverse Effect Level (LOAEL) for maternal and developmental toxicity of NaN(3) in rats were considered to be 5 and 17.5/10mg/kg/day, respectively.

Authors+Show Affiliations

MPI Research, Developmental and Reproductive Toxicology Inc., 54943 Main Street, Mattawan, MI 49071, USA. Ali.faqi@mpiresearch.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18755233

Citation

Faqi, Ali S., et al. "Maternal and Developmental Toxicity Study of Sodium Azide in Rats." Regulatory Toxicology and Pharmacology : RTP, vol. 52, no. 2, 2008, pp. 158-62.
Faqi AS, Richards D, Hauswirth JW, et al. Maternal and developmental toxicity study of sodium azide in rats. Regul Toxicol Pharmacol. 2008;52(2):158-62.
Faqi, A. S., Richards, D., Hauswirth, J. W., & Schroeder, R. (2008). Maternal and developmental toxicity study of sodium azide in rats. Regulatory Toxicology and Pharmacology : RTP, 52(2), 158-62. https://doi.org/10.1016/j.yrtph.2008.08.001
Faqi AS, et al. Maternal and Developmental Toxicity Study of Sodium Azide in Rats. Regul Toxicol Pharmacol. 2008;52(2):158-62. PubMed PMID: 18755233.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Maternal and developmental toxicity study of sodium azide in rats. AU - Faqi,Ali S, AU - Richards,Douglas, AU - Hauswirth,Judith W, AU - Schroeder,Raymond, Y1 - 2008/09/11/ PY - 2008/06/25/received PY - 2008/08/02/revised PY - 2008/08/05/accepted PY - 2008/8/30/pubmed PY - 2009/2/3/medline PY - 2008/8/30/entrez SP - 158 EP - 62 JF - Regulatory toxicology and pharmacology : RTP JO - Regul Toxicol Pharmacol VL - 52 IS - 2 N2 - Sodium azide (NaN(3)) is being proposed for use as an active ingredient to control a broad spectrum of soil borne pathogens including insects, weeds, nematodes, fungi, and bacteria. The purpose of this study was to determine the maternal and developmental toxicity of NaN(3) in rats. Sperm-positive Sprague-Dawley rats were treated with NaN(3) via oral gavage once daily from Gestation Day (GD) 6 through 19 at respective dose levels of 0, 1, 5, and 17.5mg/kg/day. From GD 10-12, the high-dose was reduced to 10mg/kg/day due to maternal mortality. Cesarean section was performed on GD 20 and implantation and resorptions sites, live and dead fetuses were counted. Fetuses were weighed, sexed externally and processed for gross external, visceral and skeletal examinations. A high rate of maternal mortality; reduced gestation body weight, gestation body weight changes and food consumption; decreased corrected body weight and corrected weight gain were observed at 17.5/10mg/kg/day. Fetal weight was also reduced at 17.5/10mg/kg/day. There were no maternal deaths, clinical signs or body weight effects that were considered related to NaN(3) at 1 and 5mg/kg/day. No increase in the incidence of malformations and variations were observed at any of the doses evaluated. Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) and the Lowest Observed Adverse Effect Level (LOAEL) for maternal and developmental toxicity of NaN(3) in rats were considered to be 5 and 17.5/10mg/kg/day, respectively. SN - 1096-0295 UR - https://www.unboundmedicine.com/medline/citation/18755233/Maternal_and_developmental_toxicity_study_of_sodium_azide_in_rats_ DB - PRIME DP - Unbound Medicine ER -